Subodh Verma M.D.

PROFESSOR

Dr. Verma is a Cardiac Surgeon-Scientist and Professor at the University of Toronto. He holds a Tier 1 Canada Research Chair in Cardiovascular Surgery and a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada.

As of February 2019, Dr. Verma has an h-index of 67, with nearly 18,000 citations in 385 publications. Dr Verma has co-authored two state-of-the-art NEJM reviews on mitral valve repair and bicuspid aortopathy. A meta-analysis led by him helped shape the recommendations of the American College of Cardiology and the Canadian Cardiovascular Society (CCS) for best revascularization choice in individuals with diabetes. 

He continues to be an active contributor to several CCS guidelines and co-authored the 2018 Diabetes Canada guidelines and 2018 AATS consensus guidelines on bicuspid aortic valve-related aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008. As well as, holding leadership roles on all five ongoing global heart failure trials in diabetes – Dapa-HF, DELIVER, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF – as well as the SELECT (semaglutide), CLEAR SYNERGY (OASIS 9) and VESALIUS (Evolocumab) trials.

Locally, he spearheads the CardioLink platform that focusses on conducting randomized trials in cardiovascular medicine, diabetes and perioperative medicine. The CardioLink trials include the SEARCH-AF (post-cardiac surgery atrial fibrillation; supported by the Heart & Stroke Foundation and investigator-initiated study grants from the pharmaceutical industry), NEWTON-CABG (graft patency after bypass surgery; supported by an investigator-initiated study grant from the pharmaceutical industry), EMPA-HEART (cardiac structure and function with the diabetes medication empagliflozin; supported by an investigator-initiated study grant from the pharmaceutical industry), CAMRA (mitral valve repair; supported by the Heart & Stroke Foundation), ACE (cerebral protection during aortic surgery), and ENABLE (diabetes and secondary prevention; supported by a Canadian Institutes of Health Research (CIHR) SPOR innovative Clinical Trials [iCT] Initiative grant) trials. Dr Verma oversees a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. This research has yielded two United States patents and is currently supported by the CIHR and HSF.

  • CLINICAL/RESEARCH INTERESTS

    • Adult Cardiac Surgery
    • Mitral Valve Repair
    • Bicuspid Aortopathy
    • Atherosclerosis – Basic and Translational Science
    • Diabetes and Cardiovascular Disease – Basic and Translational Science
    • Clinical Trials in Cardiovascular Surgery and Diabetes
    • Clinical Trials in Heart Failure and Diabetes
  • EDUCATION AND TRAINING

    • Cardiac Surgery Residency Training, University of Toronto
    • Medicine, University of Calgary, MD
    • Cardiovascular Pharmacology, University of British Columbia, PhD
    • Cardiovascular Pharmacology, University of British Columbia, MSc
  • ACTIVITIES/HONOURS/AWARDS

    • 2018/01 - present Tier 1 Canada Research Chair in Cardiovascular Surgery
    • 2015/09 Royal Society of Canada College of New Scholars, Artists and Scientists.
    • 2012/07 – 2013/06 Royal College Medal Award in Surgery
    • 2007/08 – 2017/07 Tier 2 Canada Research Chair in Atherosclerosis
    • 2010 Howard Morgan Award, International Academy of Cardiovascular Sciences
    • 2010 Canada’s Top 40 Under 40

     

     

  • PUBLICATIONS

    • Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.
    • Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD. Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
      JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587. doi: 10.1016/j.jacbts.2018.07.006.
    • Terenzi DC, Al-Omran M, Quan A, Teoh H, Verma S, Hess DA.
      Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes.
      JACC Basic Transl Sci. 2018 Nov 5;4(1):98-112. doi: 10.1016/j.jacbts.2018.10.005.
    • Verma S, Mesana TG. Mitral-Valve Repair for Mitral-Valve Prolapse. N Engl J Med. 2009 Dec 3;361(23):2261-9. doi: 10.1056/NEJMct0806111.
    • Verma S, Siu SC. Aortic Dilatation in Patients with Bicuspid Aortic Valve. N Engl J Med. 2014 May 15;370(20):1920-9. doi: 10.1056/NEJMra1207059.
    • ORCID or PubMed Link: 0000-0002-4018-8533

     

     

  • CONTACT

Contact Us

  • Chair: Dr. Terrence Yau
  • Divisional Program Administraton: Julie Wei

Toronto General Hospital
200 Elizabeth St., 4NU-432
Toronto, On M5G 2C4

Phone:
(416) 340 – 4800 Ext. 5275
Fax:
(416) 340 – 4385
Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.

Designed by: Nufuzion Design

Temerty Faculty of Medicine, University of Toronto © 2020